Sanofi (NYSE:SNY) touted data today from its 10,000-patient Lightning study, which evaluated electronic medical records of adults with Type II diabetes to study its long-acting insulin glargine injection, Toujeo.
The company found that Toujeo significantly lowered patients’ risk of experiencing severe low blood sugar compared to other long-acting insulin, like its own Lantus product.
The data, which were presented at the 11th Annual Conference on Advanced Technologies and Treatments for Diabetes, also showed that the risk of hypoglycemia was comparable between Toujeo and insulin degludec.
Sanofi said it plans to conduct further analyses to connect its findings with other clinical and economic outcomes.
“Sanofi is committed to conducting ongoing research of our medicines to help healthcare professionals better understand not only their efficacy, but also important safety information such as the risk of hypoglycemia when compared to other treatment options,” Michelle Carnahan, head of Sanofi’s North America diabetes & cardiovascular business, said in prepared remarks.
“These data add to a consistent body of evidence comparing Toujeo with long-acting insulins and strengthens our belief in using machine learning and big data to push the boundaries of real-world studies to help inform healthcare professionals’ and payers’ treatment decisions.”
